Neuroprotective effects of α2-adrenergic receptor agonists

Drug News and Perspectives

Volumn 20, Issue 3, 2007, Pages 149-154

  Weber, Bernd ^a   Steinfath, Markus ^a   Scholz, Jens ^a   Bein, Berthold ^a  

^a UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

2 (1 METHYL 2 ISOINDOLINYLMETHYL) 2 IMIDAZOLINE; ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; BRIMONIDINE; CLONIDINE; DEXMEDETOMIDINE; RAUWOLSCINE; ADRENERGIC RECEPTOR STIMULATING AGENT; ALPHA 2 ADRENERGIC RECEPTOR; IMIDAZOLINE DERIVATIVE; NEUROPROTECTIVE AGENT;

ATTENTION DEFICIT DISORDER; BRAIN ISCHEMIA; DRUG EFFECT; DRUG STRUCTURE; GILLES DE LA TOURETTE SYNDROME; HYPERTENSION; INTRAOCULAR HYPERTENSION; NEUROPROTECTION; NONHUMAN; OPEN ANGLE GLAUCOMA; REVIEW; ANIMAL; DRUG POTENTIATION; HUMAN;

ADRENERGIC AGONISTS; ANIMALS; HUMANS; IMIDAZOLINES; NEUROPROTECTIVE AGENTS; RECEPTORS, ADRENERGIC, ALPHA-2;

EID: 34250322226     PISSN: 02140934     EISSN: None     Source Type: Journal    
DOI: 10.1358/dnp.2007.20.3.1084644     Document Type: Review

References (61)

1. Suryanarayana, S., von Zastrow, M. and Kobilka, B.K. Identification of intramolecular interactions in adrenergic receptors. J Biol Chem 1992, 267: 21991-4.
2. Kobilka, B. Adrenergic receptors as models for G protein-coupled receptors. Annu Rev Neurosci 1992, 15: 87-114.
3. Beck-Sickinger, A.G. Structural characterization and binding sites of G-protein-coupled receptors. Drug Discov Today 1996, 1: 502-13.
4. Baldwin, J.M., Schertler, G.F. and Unger, V.M. An alpha-carbon template for the transmembrane helices in the rhodopsin family of G-protein-coupled receptors. J Mol Biol 1997, 272: 144-64.
5. Salminen, T., Varis, M., Nyronen, T. et al. Three-dimensional models of alpha(2A)-adrenergic receptor complexes provide a structural explanation for ligand binding. J Biol Chem 1999, 274: 23405-13.
6. Limbird, L.E. Receptors linked to inhibition of adenylate cyclase: Additional signaling mechanisms. FASEB J 1988, 2: 2686-95.
7. Richman, J.G. and Regan, J.W. Alpha 2-adrenergic receptors increase cell migration and decrease F-actin labeling in rat aortic smooth muscle cells. Am J Physiol 1998, 274: C654-62.
8. Eisenach, J.C., De Kock, M. and Klimscha, W. alpha(2)-adrenergic agonists for regional anesthesia. A clinical review of clonidine (1984-1995). Anesthesiology 1996, 85: 655-74.
9. Buerkle, H. and Yaksh, T.L. Pharmacological evidence for different alpha 2-adrenergic receptor sites mediating analgesia and sedation in the rat. Br J Anaesth 1998, 81: 208-15.
10. Takada, K., Clark, D.J., Davies, M.F. et al. Meperidine exerts agonist activity at the alpha(2B)-adrenoceptor subtype. Anesthesiology 2002, 96: 1420-6.
11. Paris, A., Philipp, M., Tonner, P.H. et al. Activation of alpha 2B-adrenoceptors mediates the cardiovascular effects of etomidate. Anesthesiology 2003, 99: 889-95.
12. Nacif-Coelho, C., Correa-Sales, C., Chang, L.L. et al. Perturbation of ion channel conductance alters the hypnotic response to the alpha2-adrenergic agonist dexmedetomidine in the locus coeruleus of the rat. Anesthesiology 1994, 81: 1527-34.
13. Dawson, C., Ma, D., Chow, A. et al. Dexmedetomidine enhances analgesic action of nitrous oxide: Mechanisms of action. Anesthesiology 2004, 100: 894-904.
14. Oliver, M.F., Goldman, L., Julian, D.G. et al. Effect of mivazerol on perioperative cardiac complications during non-cardiac surgery in patients with coronary heart disease: The European Mivazerol Trial (EMIT). Anesthesiology 1999, 91: 951-61.
15. Perioperative sympatholysis. Beneficial effects of the alpha 2-adrenoceptor agonist mivazerol on hemodynamic stability and myocardial ischemia. McSPI-Europe Research Group. Anesthesiology 1997, 86: 346-63.
16. Jaakola, M.L., Salonen, M., Lehtinen, R. et al. The analgesic action of dexmedetomidine - a novel alpha 2-adrenoceptor agonist - in healthy volunteers. Pain 1991, 46: 281-5.
17. Ghignone, M., Calvillo, O. and Quintin, L. Anesthesia and hypertension: The effect of clonidine on perioperative hemodynamics and isoflurane requirements. Anesthesiology 1987, 67: 3-10.
18. I8. Aho, M., Erkola, O., Kallio, A. et al. Dexmedetomidine infusion for maintenance of anesthesia in patients undergoing abdominal hysterectomy. Anesth Analg 1992, 75: 940-6.
19. Keranen, A., Nykanen, S. and Taskinen, J. Pharmacokinetics and side-effects of cloni dine. Eur J Clin Pharmacol 1978, 13: 97-101.
20. Werner, C., Hoffman, W.E., Thomas, C. et al. Ganglionic blockade improves neurologic outcome from incomplete ischemia in rats: Partial reversal by exogenous catecholamines. Anesthesiology 1990, 73: 923-9.
21. Hoffman, W.E., Cheng, M.A., Thomas, C. et al. Clonidine decreases plasma catecholamines and improves outcome from incomplete ischemia in the rat. Anesth Analg 1991, 73: 460-4.
22. Hoffman, W.E., Kochs, E., Werner, C. et al. Dexmedetomidine improves neurologic outcome from incomplete ischemia in the rat. Reversal by the alpha 2-adrenergic antagonist atipamezole. Anesthesiology 1991, 75: 328-32.
23. Maier, C., Steinberg, G.K., Sun, G.H. et al. Neuroprotection by the alpha 2-adrenoreceptor agonist dexmedetomidine in a focal model of cerebral ischemia. Anesthesiology 1993, 79: 306-12.
24. Kuhmonen, J., Pokorny, J., Miettinen, R. et al. Neuroprotective effects of dexmedetomidine in the gerbil hippocampus after transient global ischemia. Anesthesiology 1997, 87: 371-7.
25. Wheeler, L.A. and Woldemussie, E. Alpha-2 adrenergic receptor agonists are neuro-protective in experimental models of glaucoma. Eur J Ophthalmol 2001, 11 Suppl 2: S30-5.
26. Wheeler, L.A., Gil, D.W. and WoldeMussie, E. Role of alpha-2 adrenergic receptors in neuroprotection and glaucoma. Surv Ophthalmol 2001, 45 Suppl 3: S290-4; discussion S5-6.
27. Vidal-Sanz, M., Lafuente, M.P., Mayor, S. et al. Retinal ganglion cell death induced by retinal ischemia. Neuroprotective effects of two alpha-2 agonists. Surv Ophthalmol 2001, 45 Suppl 3: S261-7; discussion S73-6.
28. WoldeMussie, E., Ruiz, G., Wijono, M. et al. Neuroprotection of retinal ganglion cells by brimonidine in rats with laser-induced chronic ocular hypertension. Invest Ophthalmol Vis Sci 2001, 42: 2849-55.
29. Lafuente, M.P., Villegas-Perez, M.P., Mayor, S. et al. Neuroprotective effects of brimonidine against transient ischemia-induced retinal ganglion cell death: a dose response in vivo study. Exp Eye Res 2002, 74: 181-9.
30. Miyazaki, M., Nazarali, A.J., Boisvert, D.P. et al. Inhibition of ischemia-induced brain catecholamine alterations by clonidine. Brain Res Bull 1989, 22: 207-11.
31. Matsumoto, M., Zornow, M.H., Rabin, B.C. et al. The alpha 2 adrenergic agonist, dexmedetomidine, selectively attenuates ischemia-induced increases in striatal nor-epinephrine concentrations. Brain Res 1993, 627: 325-9.
32. Quigley, H.A., Nickells, R.W., Kerrigan, L.A. et al. Retinal ganglion cell death in experimental glaucoma and after axotomy occurs by apoptosis. Invest Ophthalmol Vis Sci 1995, 36: 774-86.
33. Vizi, E.S. Role of high-affinity receptors and membrane transporters in nonsynaptic communication and drug action in the central nervous system. Pharmacol Rev 2000, 52: 63-89.
34. Madison, D.V. and Nicoll, R.A. Actions of noradrenaline recorded intracellularly in rat hippocampal CA1 pyramidal neurones, in vitro. J Physiol 1986, 372: 221-44.
35. Bickler, P.E. and Hansen, B.M. Alpha 2-adrenergic agonists reduce glutamate release and glutamate receptor-mediated calcium changes in hippocampal slices during hypoxia. Neuropharmacology 1996, 35: 679-87.
36. Talke, P. and Bickler, P.E. Effects of dexmedetomidine on hypoxia-evoked gluta-mate release and glutamate receptor activity in hippocampal slices. Anesthesiology 1996, 85: 551-7.
37. Laudenbach, V., Mantz, J., Lagercrantz, H. et al. Effects of alpha(2)-adrenoceptor agonists on perinatal excitotoxic brain injury: Comparison of clonidine and dexmedetomidine. Anesthesiology 2002, 96: 134-41.
38. Milusheva, E.A. and Baranyi, M. Implication of ionotropic glutamate receptors in the release of noradrenaline in hippocampal CA1 and CAS subregions under oxygen and glucose deprivation. Neurochem Int 2003, 43: 543-50.
39. Donello, J.E., Padillo, E.U., Webster, M.L. et al. alpha(2)- Adrenoceptor agonists inhibit vitreal glutamate and aspartate accumulation and preserve retinal function after transient ischemia. J Pharmacol Exp Ther 2001, 296: 216-23.
40. Jellish, W.S., Murdoch, J., Kindel, G. et al. The effect of clonidine on cell survival, glutamate, and aspartate release in normo- and hyperglycemic rats after near complete forebrain ischemia. Exp Brain Res 2005, 167: 526-34.
41. Huang, R., Chen, Y., Yu, A.C. et al. Dexmedetomidine-induced stimulation of glutamine oxidation in astrocytes: A possible mechanism for its neuroprotective activity. J Cereb Blood Flow Metab 2000, 20: 895-8.
42. Kim, H.K., Zornow, M.H., Strnat, M.A. et al. Dexmedetomidine does not attenuate increases in excitatory amino acids after transient global ischemia in the rabbit. J Neurosurg Anesthesiol 1996, 8: 230-6.
43. Engelhard, K., Werner, C., Kaspar, S. et al. Effect of the alpha2-agonist dexmedetomidine on cerebral neurotransmitter concentrations during cerebral ischemia in rats. Anesthesiology 2002, 96: 450-7.
44. Gao, H., Qiao, X., Cantor, L.B. et al. Up-regulation of brain-derived neurotrophic factor expression by brimonidine in rat retinal ganglion cells. Arch Ophthalmol 2002, 120: 797-803.
45. Mori, K., Ozaki, E., Zhang, B. et al. Effects of norepinephrine on rat cultured microglial cells that express alphal, alpha2, beta1 and beta2 adrenergic receptors. Neuropharmacology 2002, 43: 1026-34.
46. Chao, H.M., Chidlow, G., Melena, J. et al. An investigation into the potential mechanisms underlying the neuroprotective effect of clonidine in the retina. Brain Res 2000, 877: 47-57.
47. Wittner, M., Sivenius, J. and Koistinaho, J. Alpha2-adrenoreceptor agonist, dexmedetomidine, alters acute gene expression after global ischemia in gerbils. Neurosci Lett 1997, 232: 75-8.
48. Levkovitch-Verbin, H., Harris-Cerruti, C., Groner, Y. et al. RGC death in mice after optic nerve crush injury: oxidative stress and neuroprotection. Invest Ophthalmol Vis Sci 2000, 41: 4169-74.
49. Dahmani, S., Rouelle, D., Gressens, P. et al. Effects of dexmedetomidine on hippocampal focal adhesion kinase tyrosine phosphoryla-tion in physiologic and ischemic conditions. Anesthesiology 2005, 103: 969-77.
50. MacMillan, L.B., Hein, L., Smith, M.S. et al. Central hypotensive effects of the alpha2a-adrenergic receptor subtype. Science 1996, 273: 801-3.
51. Altaian, J.D., Trendelenburg, A.U., MacMillan, L. et al. Abnormal regulation of the sympathetic nervous system in alpha2A-adrenergic receptor knockout mice. Mol Pharmacol 1999, 56: 154-61.
52. Hein, L., Altman, J.D. and Kobilka, B.K. Two functionally distinct alpha2-adrenergic receptors regulate sympathetic neurotransmission. Nature 1999, 402: 181-4.
53. Lakhlani, P.P., MacMillan, L.B., Guo, T.Z. et al. Substitution of a mutant alpha2a-adrenergic receptor via "hit and run" gene targeting reveals the role of this subtype in sedative, analgesic, and anesthetic-sparing responses in vivo. Proc Natl Acad Sci U S A 1997, 94: 9950-5.
54. Stone, L.S., MacMillan, L.B., Kitto, K.F. et al. The alpha2a adrenergic receptor subtype mediates spinal analgesia evoked by alpha2 agonists and is necessary for spinal adrenergic-opioid synergy. J Neurosci 1997, 17: 7157-65.
55. Hunter, J.C., Fontana, D.J., Hedley, L.R. et al. Assessment of the role of alpha2-adrenoceptor subtypes in the antinociceptive, sedative and hypothermic action of dexmedetomidine in transgenic mice. Br J Pharmacol 1997, 122: 1339-44.
56. Sallinen, J., Link, R.E., Haapalinna, A. et al. Genetic alteration of alpha 2C-adrenoceptor expression in mice: influence on locomotor, hypothermic, and neurochemical effects of dexmedetomidine, a subtype-nonselective alpha 2-adrenoceptor agonist. Mol Pharmacol 1997, 51: 36-46.
57. Ma, D., Hossain, M., Rajakumaraswamy, N. et al. Dexmedetomidine produces its neuroprotective effect via the alpha 2A-adrenoceptor subtype. Eur J Pharmacol 2004, 502: 87-97.
58. Paris, A., Mantz, J., Tonner, P.H. et al. The effects of dexmedetomidine on perinatal excitotoxic brain injury are mediated by the alpha2A-adrenoceptor subtype. Anesth Analg 2006, 102: 456-61.
59. Wang, Q., Zhao, J., Brady, A.E. et al. Spinophilin blocks arrestin actions in vitro and in vivo at G protein-coupled receptors. Science 2004, 304: 1940-4.
60. Weber, B., Schaper, C., Scholz, J. et al. Interaction of the amyloid precursor like protein 1 with the alpha(2A)-adrenergic receptor increases agonist-mediated inhibition of adenylate cyclase. Cell Signal 2006, 18: 1748-57.
61. Selkoe, D.J. Alzheimer's diseases: Genes, proteins, and therapy. Physiol Rev 2001, 81: 741-66.